FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4311759933> ?p ?o ?g. }

• W4311759933 abstract "Nadofaragene firadenovec is a gene therapy for bacillus Calmette-Guérin (BCG)-unresponsive non-muscle-invasive bladder cancer (NMIBC) undergoing Food and Drug Administration review. Pembrolizumab is approved for treating patients with BCG-unresponsive NMIBC with carcinoma in situ (CIS). We evaluated the cost-effectiveness of these treatments compared with a hypothetical therapeutic alternative, at a willingness-to-pay threshold of $150 000 per quality-adjusted life-year (QALY) gained, in CIS and non-CIS BCG-unresponsive NMIBC populations.We developed a Markov cohort simulation model with a 3-month cycle length and lifetime horizon to estimate the total costs, QALYs, and cost per additional QALY from the health sector perspective. Clinical inputs were informed by results of single-arm clinical trials evaluating the treatments, and systematic literature reviews were conducted to obtain other model inputs. Sensitivity analyses were conducted to assess uncertainty in model results.Nadofaragene firadenovec, at a placeholder price 10% higher than the price of pembrolizumab, had an incremental cost-effectiveness ratio of $263 000 and $145 000 per QALY gained in CIS and non-CIS populations, respectively. Pembrolizumab had an incremental cost-effectiveness ratio of $168 000 per QALY gained for CIS. A 5.4% reduction in pembrolizumab's price would make it cost-effective. The model was sensitive to many inputs, especially to the probabilities of disease progression, initial treatment response and durability, and drug price.The cost-effectiveness of nadofaragene firadenovec will depend upon its price. Pembrolizumab, although not cost-effective in our base-case analysis, is an important alternative in this population with an unmet medical need. Comparative trials of these treatments are warranted to better estimate cost-effectiveness." @default.
• W4311759933 created "2022-12-28" @default.
• W4311759933 creator A5006730126 @default.
• W4311759933 creator A5011359418 @default.
• W4311759933 creator A5028254667 @default.
• W4311759933 creator A5050666513 @default.
• W4311759933 creator A5056528203 @default.
• W4311759933 creator A5061398003 @default.
• W4311759933 creator A5083493729 @default.
• W4311759933 date "2022-12-01" @default.
• W4311759933 modified "2023-10-14" @default.
• W4311759933 title "Cost-Effectiveness of Nadofaragene Firadenovec and Pembrolizumab in Bacillus Calmette-Guérin Immunotherapy Unresponsive Non–Muscle Invasive Bladder Cancer" @default.
• W4311759933 cites W1497833551 @default.
• W4311759933 cites W1499603342 @default.
• W4311759933 cites W1967090328 @default.
• W4311759933 cites W1987030333 @default.
• W4311759933 cites W1995365262 @default.
• W4311759933 cites W2022399786 @default.
• W4311759933 cites W2042179480 @default.
• W4311759933 cites W2050256434 @default.
• W4311759933 cites W2052354141 @default.
• W4311759933 cites W2066628750 @default.
• W4311759933 cites W2072163008 @default.
• W4311759933 cites W2091808986 @default.
• W4311759933 cites W2103257412 @default.
• W4311759933 cites W2103561213 @default.
• W4311759933 cites W2105935489 @default.
• W4311759933 cites W2108145868 @default.
• W4311759933 cites W2143401180 @default.
• W4311759933 cites W2144125109 @default.
• W4311759933 cites W2162756611 @default.
• W4311759933 cites W2165562791 @default.
• W4311759933 cites W2177496891 @default.
• W4311759933 cites W2181032107 @default.
• W4311759933 cites W2331426679 @default.
• W4311759933 cites W2344477985 @default.
• W4311759933 cites W2398245286 @default.
• W4311759933 cites W2581289368 @default.
• W4311759933 cites W2765431857 @default.
• W4311759933 cites W2792261741 @default.
• W4311759933 cites W2792717752 @default.
• W4311759933 cites W2886978124 @default.
• W4311759933 cites W2888661558 @default.
• W4311759933 cites W2893171711 @default.
• W4311759933 cites W2901308442 @default.
• W4311759933 cites W2901315920 @default.
• W4311759933 cites W2903162255 @default.
• W4311759933 cites W2905414330 @default.
• W4311759933 cites W2970692557 @default.
• W4311759933 cites W2994733409 @default.
• W4311759933 cites W3009410127 @default.
• W4311759933 cites W3016448636 @default.
• W4311759933 cites W3049389441 @default.
• W4311759933 cites W3092636925 @default.
• W4311759933 cites W3108799736 @default.
• W4311759933 cites W3110303110 @default.
• W4311759933 cites W3145816918 @default.
• W4311759933 cites W3164781831 @default.
• W4311759933 cites W4206608028 @default.
• W4311759933 cites W4242669880 @default.
• W4311759933 cites W4251083747 @default.
• W4311759933 cites W594984707 @default.
• W4311759933 doi "https://doi.org/10.1016/j.jval.2022.12.005" @default.
• W4311759933 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36529422" @default.
• W4311759933 hasPublicationYear "2022" @default.
• W4311759933 type Work @default.
• W4311759933 citedByCount "2" @default.
• W4311759933 countsByYear W43117599332023 @default.
• W4311759933 crossrefType "journal-article" @default.
• W4311759933 hasAuthorship W4311759933A5006730126 @default.
• W4311759933 hasAuthorship W4311759933A5011359418 @default.
• W4311759933 hasAuthorship W4311759933A5028254667 @default.
• W4311759933 hasAuthorship W4311759933A5050666513 @default.
• W4311759933 hasAuthorship W4311759933A5056528203 @default.
• W4311759933 hasAuthorship W4311759933A5061398003 @default.
• W4311759933 hasAuthorship W4311759933A5083493729 @default.
• W4311759933 hasConcept C112930515 @default.
• W4311759933 hasConcept C121608353 @default.
• W4311759933 hasConcept C126322002 @default.
• W4311759933 hasConcept C143998085 @default.
• W4311759933 hasConcept C2777701055 @default.
• W4311759933 hasConcept C2780057760 @default.
• W4311759933 hasConcept C2780352672 @default.
• W4311759933 hasConcept C3019080777 @default.
• W4311759933 hasConcept C71924100 @default.
• W4311759933 hasConcept C72563966 @default.
• W4311759933 hasConceptScore W4311759933C112930515 @default.
• W4311759933 hasConceptScore W4311759933C121608353 @default.
• W4311759933 hasConceptScore W4311759933C126322002 @default.
• W4311759933 hasConceptScore W4311759933C143998085 @default.
• W4311759933 hasConceptScore W4311759933C2777701055 @default.
• W4311759933 hasConceptScore W4311759933C2780057760 @default.
• W4311759933 hasConceptScore W4311759933C2780352672 @default.
• W4311759933 hasConceptScore W4311759933C3019080777 @default.
• W4311759933 hasConceptScore W4311759933C71924100 @default.
• W4311759933 hasConceptScore W4311759933C72563966 @default.
• W4311759933 hasLocation W43117599331 @default.
• W4311759933 hasLocation W43117599332 @default.
• W4311759933 hasOpenAccess W4311759933 @default.
• W4311759933 hasPrimaryLocation W43117599331 @default.

• next